Introduction
Sickle cell disease (SCD) is an inherited disorder characterized in part by transient acute painful episode (APE) episodes, which occur with varying frequency and severity.
A number of factors may lead to the development of APE, including hypoxia and clinical dehydration, which promotes hemoglobin S polymerization and vascular obstruction. The ensuing pain is believed to be nociceptive secondary to obstruction of the microcirculation and tissue ischemia.(1) Infection and inflammation may promote coagulation cascades, leukocyte activation, and endothelial activation, which may further contribute to vascular obstruction.(2,3) These painful crises are unpredictable, but may follow exposure to cold or, less commonly, emotional stress, exercise, or alcohol. (1, 4) Hematologic risk factors include elevated hematocrit, known to be increased with concomitant alpha thalassemia, and low fetal hemoglobin levels. (5, 6) The rise in fetal hemoglobin seen with the administration of hydroxyurea in SCD patients is believed to account for its reduction in the frequency of APE.(7) Despite the advances that have been made in APE prevention with the increasing use of hydroxyurea and exchange transfusion, the effective management of APE remains a challenge. (8, 9) Heterogeneous expression has made APE difficult to accurately diagnose and systematically manage. The principal manifestation of APE is pain, which is a subjective phenomenon, and its traditional definition has relied upon patient report. The start of APE is often defined as the time of onset of pain severe enough to warrant hospitalization and the administration of opioid analgesia.(10) However, there is not a reliable objective marker of APE. Such a marker would be extremely useful in clinical research of APE and would allow observation of treatment effect during APE and resolution.(11) Rheological changes have found minor fluctuations in poorly deformable dense cells during steady state and larger increases during overt APE. (10, 12) Several acute phase reactants have been found to exhibit similar patterns of transient low-level increase during steady state and more significant elevations during APE. Such fast responding reactants include Creactive protein (CRP) and serum amyloid A (SAA). The slower responding proteins include fibrinogen, orosomucoid, sialic acid, and concanavalin-A binding protein. (10, 11, 13) Other possible markers of APE include rises in erythrocyte sedimentation rate, (14) dense cells, (15) and plasma viscosity. (12, 16) We have performed a broader high-throughput screening of the SCD plasma proteome using surface-enhanced laser desorption/ionization time of flight mass spectrometry (SELDI-TOF MS) to screen for candidate proteins that might serve as biomarkers of APE in SCD patients.
Design and Methods

Patient selection
Study participants were enrolled with informed consent on a research protocol approved by the institutional review board of the National Heart, Lung and Blood Institute. For inclusion, these sickle cell patients presented to the Clinical Center with APE requiring hospitalization for pain management. Excluded patients were those on a chronic transfusion regimen, pregnant, nursing, or with hemoglobin SC disease. Patients who were clinically diagnosed at the time of hospital admission with bacterial infection, pneumonia, acute chest syndrome, or splenic sequestration were also excluded. Plasma samples were collected and frozen in almost all cases during the first 24 hours of APE, and matched with samples from the same patient at least 10 days before or 4 
Proteomic screening
We performed SELDI-TOF MS screening and statistical analysis, previously described in great detail. (17) Briefly, each plasma sample was fractionated by ion exchange chromatography, and selected fractions were bound to specific affinity matrices and submitted to SELDI-TOF MS. Significant alterations in peak abundance were identified using CiphergenExpress software application. Peaks with the lowest P values (p<0.0001)
were selected for additional analysis. Preliminary peak identifications were based on our published studies of peaks with similar charge to mass ratios. (17) Because of the matched-pair study design, no adjustments for gender or other demographic variables was necessary.
ApoA-I and SAA measurement
Plasma apoA-I levels were measured by Beckman Coulter IMMAGE rate nephelometry (Ramsey, MN, USA), according to the manufacturer's recommendations.
SAA levels were measured using a standard immunoassay kit (US Biological, Swampscott, MA, USA).
Statistical analysis
Paired statistics were used to calculate P values by Wilcoxon signed-rank test.
Spearman correlation coefficients were calculated using Prism 4.01 (GraphPad Prism 4 software, San Diego, CA, USA). For these standard statistical tests, statistical significance was assumed for p<0.05.
Results
Standard clinical laboratory variables
The paired analysis of the 26 patient cohort standard hematological and biochemical indices in steady state and APE revealed several significant changes. SCD patients undergoing APE exhibited significantly lower levels of hemoglobin, hematocrit, red blood cells, total protein, and albumin as well as increased levels of LDH, absolute reticulocytes, and leukocytes (Table 1) , consistent with accelerated hemolysis and inflammatory changes during APE.
SELDI-TOF MS and immunoassay evaluations
Spectral analysis for the 26 patients was performed using the CiphergenExpress software program and analyzed for intensity differences between the steady state and APE conditions. The peaks with the highest statistical significance were found in our previously published study. (17) Protein purification and high resolution mass spectroscopy identified similar peaks to be the vascular disease markers serum amyloid A (SAA) and apolipoprotein A-I (apoA-I) at 11,757 and 28,133 kDa. (17) Repeated Random
Forest and logistic regression modeling consistently showed higher abundance of an 11.7 kDa protein in those patients with APE when compared to steady state levels. To confirm the identity of this peak in the current study, we performed parallel immunoassays for SAA in the corresponding unfractionated plasma specimens. The SELDI-TOF MS peak intensities of the 11.7 kDa peak demonstrated a significant correlation with SAA immunoassay levels (r =0.85, p<0.0001), confirming the identity of the 11.7 kDa peak as SAA (Figure 1a ), and consistent with our previous high-resolution mass spectroscopy identification of this peak. (17) This correlation remained equally high even if the highest 4 or even 10 outliers were excluded. More importantly, we found that the level of SAA was significantly elevated during APE when compared to steady state ( Figure 1b) .
We also noted that 4 subjects from the 26 patient cohort exhibited extremely high levels of SAA during APE when compared to the rest of the group (median 6.5 vs. 413.5 µg/mL, p = 0.002). Interestingly, these four patients with the highest SAA levels during APE were distinguishable from the rest of the patients by several clinical characteristics. In addition to SAA, we also identified a peak at 28.1 kDa that was consistently lower in abundance in the APE group in every fraction and affinity surface type evaluated. The 28.1 kDa peak intensities showed significant correlation to the apoA-I immunoassay levels (r=0.49, p<0.0002) (Figure 2a) , accordingly, apoA-I immunoassay levels during APE were significantly lower when compared to steady state (Figure 2b ).
Assignment of the 28.1 kDa peak as apoA-I is consistent with our previous identification of this peak by high resolution mass spectroscopy. (17) Our data also demonstrated that the ratio of SAA/ApoA-I rose significantly from APE compared to steady state, rising in 81% of the patients (Fig. 3) , suggesting that the two markers in combination may be a biomarker of APE.
Discussion
Acute painful episode in sickle cell disease includes an inflammatory response, thought to be mediated by macrophages infiltrating ischemic tissues and is associated with an increase in acute phase reactants during APE. (24) SAA is a classic positive acute phase reactant known to increase within six to ten hours of tissue injury, (25, 26) ultimately reaching levels 1000-fold baseline. (27) In this study, we detected the elevation of an 11.7 kDa peak during APE, which demonstrated the highest statistical significance in both univariate and multivariate analyses. In another study of markers of pulmonary hypertension in SCD, we found a very similar peak, that upon purification and high resolution mass spectroscopy was SAA, confirmed by immunoassay. (17) In the present study, we find that the similar 11.7 kDa peak once again correlated very significantly with the SAA immunoassays of unfractionated plasma from the same specimens.
Of interest, in our study we also noted that four patients showed distinctive characteristics form the rest of the patients by principal component analysis. These four patients after initial presentation with APE went on to develop clinically severe APE with end-organ damage. These patients were distinguished by very high levels of SAA, and correlated with largest increments in WBC during APE. This subgroup also displayed a particularly significant increase in reticulocyte count during APE, suggesting accelerated hemolysis. During steady state, the subgroup had lower MCV's than the others consistent with less hydroxyurea use and/or concurrent alpha thalassemia trait, both known risk factors for more frequent and potentially more symptomatic APE. (28, 29) We also found that a 28.1 kDa peak was decreased during APE in every fractionsurface combination, correlating strongly with apoA-I immunoassay. During the general acute phase response, total cholesterol, high density lipoprotein (HDL), and apoA-I are known to be diminished. (30, 31) Furthermore, a published study from our group has linked low levels of a similar peak to vasculopathy and pulmonary hypertension in SCD, confirmed by high-resolution mass spectroscopy and immunoassay to be apoA-I. (17) Alterations in these markers have been reported even during the steady state of SCD. It has previously been reported that apoA-I levels are lower in sickle cell patients compared to the general population. It is fascinating that steady state levels of SAA and apoA-I, two well-established markers and mediators of vascular dysfunction and atherosclerosis, appear from our previous study to be markers of endothelial dysfunction and pulmonary hypertension (17) and, in the current study, become even more abnormal during APE. This suggests that these markers describe and potentially even mediate a state of chronic vasculopathy in SCD that worsens acutely during APE, consistent with our previous evidence that pulmonary hypertension acutely worsens during APE. (36) We propose that the development of apoA-I mimetic drugs or induction of higher apoA-I levels merit investigation for potential therapeutic utility in the acute vasculopathy of APE or the chronic vasculopathy of SCD.(37) 
